About Company
Advance to the Mainland China market
- Renewed ISO 13485 Certification (ISO 13485:2016)
2019
2018
- AAE passed an on-site inspection by the US FDA
- BOBC received Taiwan FDA approval for the ologen® Collagen Matrix
2017
- GMP (Taiwan) certified
2016
- Indian subsidiary, AAI launch
- Biocornea clinical trial
2015
Horizon2020
- Clinical trial for Biocornea Type E.
- Horizon2020 grant (EUR 5.99M).
2014
First 5-Year clinical results
- Aongen® Collagen Membrane registration with TFDA.
- First 5-Year clinical results announce at WOC
2013
- 23 SCI/SCIE Publications
- New Indications Approved
2012
5 Years
- Aongen Collagen Matrix 510K Clearance
- Innovatiefonds MKB+ (EUR 3M)
- BOBC Listed on Taiwan Emerging Stock Markets
2011
- Sales cover 30 countries
- AgentschapNL Grant(EUR 0.5M)
2010
- CMDCAS Certificate
- 32 Patents Filed
- 8 on-hand
2009
ologen Collagen Matrix
- ologen® Collagen Matrix Launch
- FDA 510K Clearance
- SenterNovem Grant (EUR 0.3M)
2008
AAE
- AAE B.V. Established
- ISO 13485
- CE Certificate
2007
BOBC
- BOBC Established
- ISO13485
2019
- Oct.
BOBC announced the development of Collagen Lens, a protective corneal shield derived from the company’s proprietary Biocornea platform.
- Feb.
BOBC and Aeon Astron Europe B.V. renewed their respective ISO 13485 Certification (ISO 13485:2016).
- Jan.
BOBC received a US invention patent for a novel fish skin-based biomaterial.
2018
- Oct.
- BOBC received the CE Mark (Class III Medical Device) for the Aongen® Collagen Membrane.
- The Biocornea clinical trial received approval from the German BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) to expand the number of study sites.
- Aug.
- BOBC became GMP (Brazil-ANVISA) certified for production.
- BOBC received a Korea invention patent for a novel fish skin-based biomaterial.
- Jul.
Subsidiary Aeon Astron Europe B.V. passed an on-site inspection by the US Food and Drug Administration (FDA) successfully.
- Jun.
BOBC received Taiwan FDA approval for the ologen® Collagen Matrix.
- Mar.
BOBC received a European invention patent for technology advances made in the field of biomaterials.
- Jan.
BOBC received a Korea invention patent for technology advances made in the field of biomaterials.
2017
- Aug.
BOBC received a Japan invention patent for technology advances made in the field of biomaterials.
- Jul.
BOBC became GMP (Taiwan) certified to produce the Biocornea on top of existing product lines.
- May
BOBC received an Indonesia invention patent for technology advances made in the field of biomaterials.
2016
- Dec.
BOBC received a Taiwan invention patent for technology advances made in the field of ophthalmology.
- Nov.
BOBC received an international branding subsidy of NTD $2.5 Million from the Department of Economic Development, Taipei City Government.
- Apr.
Indian subsidiary, Aeon Ajanta India Pvt. Ltd., officially launched.
- Mar.
The Biocornea clinical trial at the University Hospital of the University of Cologne (Uniklinik Köln, Universität zu Köln) began.
- Feb.
BOBC received a German invention patent for technology advances made in the field of ophthalmology.
2015
- Dec.
- Aeon Astron Europe B.V. Obtained IRB approvals from the German Federal Institute for Drugs and Medical Devices (BfArM) and the University of Cologne to start clinical trial for ologen® Biocornea.
- Aeon Astron Europe B.V. with it its lead program on ologen® Biocornea is part of a consortium of leading universities in Europe. The consortium ARREST BLINDNESS is recipient of EUR 5.99 million Horizon2020 grant.
- Obtained medical device approval and registration from the Taiwan Food and Drug Administration, Ministry of Health and Welfare for Aongen® Collagen Membrane.
- May
BOBC obtained certified High Tech Industry status from the Taiwan Industrial Development Bureau, Ministry of Economic Affairs.
2014
- May
- USA HCPCS public hearing.
- ologen® Collagen Matrix obtained KGMP certificate.
- Apr.
ologen® Collagen Matrix vs. MMC in Trabeculectomy- A Five-Year report at 2014 WOC, Tokyo.
2013
- Nov.
- ologen® Collagen Matrix for congenital glaucoma: comparative results at 2013 AAO, New Orleans.
- ologen® Collagen Matrix attained health approval in Iran.
- A US 12-month retrospective review using ologen® Collagen Matrix with Ex-PRESS in trabeculectomy on J Glaucoma.
- Oct.
ologen® Collagen Matrix attained health approval in Peru.
- Jul.
ologen® Collagen Matrix for congenital glaucoma: presentation at 2013 WGC, Vancouver.
- Jun.
ologen® Collagen Matrix for congenital glaucoma: case report at 2013 SOE Congress, Copenhagen.
- Mar.
ologen® Collagen Matrix attained health approval in Mexico.
- Jan.
The number of ologen Collagen Matrix’s SCI/SCIE publications reaches fifteen (15).
2012
- Aug.
ologen® Collagen Matrix attained health approval in Vietnam.
- Jul.
ologen® Collagen Matrix attained health approval in Saudi Arabia.
- May
Founding of the Network of Excellence in Corneal Regeneration (NEXCR).
- Mar.
- Aeon Astron Europe B.V. received grant EURO 3 million for its BioCornea project from Innovatiefond MKB , Dept. of Economic Affairs of the Netherlands.
- ologen® Collagen Matrix attained health approval in Argentina.
2011
- Dec.
Aeon Astron Europe B.V. received grant EURO 500,000 from AgentschapNL, Dept. of Economic Affairs of the Netherlands.
- Oct.
Aeon Astron Europe B.V. and Aeon Astron USA became 100% reinvested subsidiaries of BOBC.
- Sep.
- BOBC awarded 2011 Taipei Bio-driven Award
- ologen® Collagen Matrix attained Canada Medical Device License.
- Aug.
ologen® Collagen Matrix is reimbursed in Tunisia.
- May
ologen® Collagen Matrix attained health approval in Egypt.
- Jan.
Aeon Astron Europe B.V. is the Glaucoma Industry member of WGA.
2010
- Aug.
ologen® Collagen Matrix attained health approval in Jordan.
- Jul.
ologen® Collagen Matrix obtained CMDCAS certificate.
- Apr.
ologen® Collagen Matrix is reimbursed by the Medicare System in Sweden.
- Jan.
ologen® Collagen Matrix is reimbursed by the General Insurance Agency in Czech.
2009
- Dec.
- Aeon Astron Europe B.V. received grant EURO 300,000 for its BioCornea project from AgentschapNL, Dept. of Economic Affairs of the Netherlands.
- ologen® Collagen Matrix attained Indian health registration certificate.
- Aug.
ologen® and Aongen® received US FDA 510K clearance letter.
2008
- Nov.
The brand oculusgen has been changed to ologen.
- Mar.
Collagen Matrix and Bandage Lens CE certificates attained.
- Feb.
Aeon Astron Europe B.V. ISO 13485 certificate was obtained.
- Jan.
Aeon Astron Europe B.V. was established.
2007
- Nov.
BOBC attained ISO 13485:2003 certificate.
- May
Body Organ Biomedical Corporation was established.
Body Organ Biomedical Corporation
Tel：+886 2 2659 7698
E-mail：contactus@aeonastron.com
Add：5F., No. 322, Sec. 1, Neihu Rd., Neihu Dist., Taipei City 114, Taiwan (R.O.C.)